‘Serious concerns’ about low standards of evidence for cancer drug approvals

The quality of clinical trials for new cancer therapies leaves room for improvement, according to an article in the latest BMJ. An analysis of 54 pivotal studies, which led to the European Medicines Agency (EMA) approval of 32 new cancer drugs between 2014 and 2016, found almost half the trials (49%) were at high risk ...

Already a member?

Login to keep reading.

© 2022 the limbic